We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib.
- Authors
NAOKI FUKUDA; XIAOFEI WANG; AKIHIRO OHMOTO; TETSUYA URASAKI; YASUYOSHI SATO; KENJI NAKANO; MASATOSHI NISHIZAWA; MAYU YUNOKAWA; MAKIKO ONO; JUNICHI TOMOMATSU; SHUNJI TAKAHASHI
- Abstract
Background/Aim: Neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated with poor prognosis for radioactive iodine ablation refractory differentiated thyroid cancer (RR-DTC). Little is known whether NLR can be a tumor marker for RR-DTC patients treated with lenvatinib. Patients and Methods: We retrospectively analyzed RR-DTC patients treated with lenvatinib. NLR was calculated at 4 points before and during lenvatinib treatment. Results: The median NLR value increased at the start of lenvatinib treatment, compared to 6 months prior to initiation of lenvatinib treatment. The median overall survival was significantly longer in patients with the lower NLR (<3) at the start of lenvatinib treatment. The median NLR values decreased when the patients achieved best tumor response, and increased again upon disease progression. Conclusion: NLR values vary before and during lenvatinib treatment, suggesting that this ratio can reflect disease activity of RR-DTC. NLR can supportively be used as a tumor marker of RR-DTC and an indicator for starting lenvatinib treatment.
- Subjects
ANTINEOPLASTIC agents; THYROID cancer treatment; NEUTROPHILS; LYMPHOCYTES; CANCER invasiveness
- Publication
In Vivo, 2020, Vol 34, Issue 2, p709
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.11828